目的 统计上海交通大学医学院附属苏州九龙医院（简称苏州九龙医院）近3年抗肿瘤靶向药物的使用情况，分析用药趋势，为抗肿瘤靶向药物的合理使用提供参考。方法 采用限定日剂量（DDD），对2017—2019年苏州九龙医院抗肿瘤靶向药物的品种、规格、销售数量、销售金额、用药频度（DDDs）、日均费用（DDC）和排序比（B/A）等进行统计分析。结果 苏州九龙医院近3年抗肿瘤靶向药物使用数量和使用金额逐年增长，奥希替尼在所有抗肿瘤靶向药物中增长最为迅速，DDDs已升至第一位。大分子抗体药物增速较快，DDC也普遍偏高，销售金额将赶超小分子激酶抑制剂。埃克替尼的B/A连续3年≥2.00，利妥昔单抗的B/A综合最低。结论 随着医疗政策的倾斜、药品降价，抗肿瘤靶向药物将使更多的患者获益。

Objective To count the use of anti-tumor targeted drugs in Suzhou Kowloon Hospital in recent 3 years, analyze the trend of drug use, and provide reference for the rational use of anti-tumor targeted drugs. Methods The variety, specification, quantity of sales, amount of sales, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) of anti-tumor targeted drugs of Suzhou Kowloon Hospital from 2017-2019 were analyzed by defined daily dose(DDD). Results In recent 3 years, the quantity and amount of anti-tumor targeted drugs increased year by year. Osimertinib was the fastest growing of all anti-tumor targeted drugs, and DDDs had risen to the first place. The growth rate of macromolecular antibody drugs was fast, and DDC was generally on the high side. The sales amount will catch up with and surpass that of small molecule kinase inhibitors. While B/A of Icotinib was ≥ 2.00 for 3 consecutive years, B/A of rituximab was the lowest. Conclusion With the inclination of medical policy and drug price reduction, more and more patients will benefit from anti-tumor targeted drugs.

R979.1